Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Equity Average (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Equity Average data on record, last reported at $509.1 million in Q3 2025.

  • For Q3 2025, Equity Average fell 17.68% year-over-year to $509.1 million; the TTM value through Sep 2025 reached $509.1 million, down 17.68%, while the annual FY2024 figure was $556.8 million, 33.04% up from the prior year.
  • Equity Average reached $509.1 million in Q3 2025 per VRDN's latest filing, down from $559.8 million in the prior quarter.
  • Across five years, Equity Average topped out at $689.6 million in Q4 2024 and bottomed at $102.5 million in Q2 2021.
  • Average Equity Average over 5 years is $369.7 million, with a median of $362.8 million recorded in 2023.
  • Peak YoY movement for Equity Average: skyrocketed 618.98% in 2021, then fell 17.68% in 2025.
  • A 5-year view of Equity Average shows it stood at $196.2 million in 2021, then soared by 104.96% to $402.0 million in 2022, then decreased by 9.76% to $362.8 million in 2023, then surged by 90.07% to $689.6 million in 2024, then decreased by 26.18% to $509.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were $509.1 million in Q3 2025, $559.8 million in Q2 2025, and $638.1 million in Q1 2025.